Trials / Recruiting
RecruitingNCT06864624
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Sunvozertinib as Neoadjuvant and Adjuvant Therapy in Stage II-IIIB Non-small-cell Lung Cancer Patients With EGFR Exon 20 Insertion Mutation: a Single-arm, Phase 2 Study (WU-KONG20)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Tang-Du Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunvozertinib | Neoadjuvant stage: 300mg for 12 weeks Adjuvant stage: 300mg for first 4 weeks, then 150mg for up to 2 years |
Timeline
- Start date
- 2025-02-18
- Primary completion
- 2026-12-01
- Completion
- 2029-06-01
- First posted
- 2025-03-07
- Last updated
- 2025-07-25
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06864624. Inclusion in this directory is not an endorsement.